United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $511.09, for a total value of $4,855,355.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $165,819,572.87. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Up 0.5%

UTHR opened at $512.70 on Wednesday. The firm has a market cap of $21.99 billion, a PE ratio of 18.34, a P/E/G ratio of 2.55 and a beta of 0.56. The business has a fifty day simple moving average of $529.27 and a 200-day simple moving average of $539.68. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several large investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC bought a new stake in United Therapeutics during the second quarter valued at about $277,000. Cerity Partners LLC boosted its holdings in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its stake in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on UTHR. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.